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Background (318 words)
Cytomegalovirus represents a persisting challenge to transplant patients due to its direct and indirect effects decreasing graft and patient survival [1] [2] [3] [4] . Significant progress has been made in the clinical management of CMV replication post-transplantation through the concerted action of stratifying CMV risk according to CMV IgG serostatus of donor and recipient pairs, implementing prophylactic or preemptive antiviral strategies, and developing consensus definitions and guidelines [5] [6] [7] . Central to current medical practice is the sensitive and specific detection and quantification of CMV replication for clinical studies as well as for therapy decisions 7, 8 . Despite known limitations, this is widely approached by determining CMV DNA loads in blood using quantitative nucleic acid testing (QNAT) [9] [10] [11] . Although CMV QNAT is now clinically available with turn-around times of less than 6 hours, results from quality assurance programs and dedicated multicenter studies indicated that the CMV DNA load results may be highly variable across different centers and across different laboratorydeveloped and commercial assays [12] [13] [14] . Normalization to an external reference sample was shown to significantly reduce the spread of the reported viral load results, thus providing an important rationale for developing commutable calibrators such as the 1 st WHO-approved CMV International Standard (1 st -WHO-IS-CMV) [15] [16] [17] . Indeed, an international multicenter study demonstrated previously that CMV load variability is mitigated across all participating laboratories when all steps and variables of the procedure were standardized such as using defined plasma volumes, automated DNA extraction and target amplification, and integrating calibration to 1 st -WHO-IS-CMV as in the FDA-approved COBAS AmpliPrep/COBAS TaqMan CMV (in short: Roche-CAP/CTM-CMV) 18 . Despite an excellent performance record in our laboratories since its routine introduction 19 , the Roche-CAP/CTM-CMV showed under-quantification and false-negative results of two quality assurance samples providing the same viral material in a lower and a higher dilution, respectively (UK-NEQAS-2014 distribution
; specimen 2194 and 2195) 20 . This observation elicited considerable uncertainty about the cause and the impact on clinical management, in several transplant centers including ours.
Objectives (149 words)
To determine the reasons for the Roche-CAP/CTM-CMV to fail the UK-NEQAS-2014 distribution 3521, we hypothesized that sequence variations in the CMV-UL54 target region were responsible. Since the manufacture declined to provide this information or to reveal the target region, we identified two publications through a literature search 21, 22 , which suggested the presumed target region of the Roche-CAP/CTM-CMV to reside in the CMV UL54 DNA polymerase gene. We determined the sequence in the presumed UL54 target of the Roche-CAP/CTM-CMV resulting in quantification failure and compared the results to 329 available CMV GenBank sequences. We developed four new in-house CMV-UL54 QNAT assays designed to accommodate UL54 sequence variations but differing in amplicon length. The assays were validated using reference and variant plasmid dilutions, 1 st -WHO-IS-CMV, UK-NEQAS-2014 sample, as well as 107 frozen and 69 prospectively collected plasma samples submitted for CMV load, with and without DNase-digestion prior to nucleic acid extraction.
Study design (669 words)

Primers, probes, and plasmids
Primers and probes used for amplification, QNAT and sequencing are indicated in Table 1 . Plasmids harboring the presumed target sequence of CMV-strain AD169 and the UK-NEQAS-2014 sequence were chemically synthesized into the pUC57 plasmid (Eurogentec, Belgium) as denoted pCMV-AD169-UL54 and pCMV-UKNEQAS2014-UL54.
Plasma samples
176 plasma samples tested for CMV load quantification were available from kidney and liver transplant patients consisting of 107 frozen samples for a retrospective study, and 69 prospectively collected samples. In 111 cases (49 retrospective; 62 prospective), CMV loads were in the linear range of the Roche assay, above the lower limit of quantification (LLOQ 150 copies/mL; 137 IU/mL) in 50 cases (all retrospective) below the limit of detection (LOD 91 IU/mL) of the CAP/CTM-CMV assay 23 , and in 15 cases (8 retrospective; 7 prospective) above the LOD of 91 IU/mL, but below LLOQ of 137 IU/mL (detected, but not quantifiable). Basel-CMV-UL111a-77bp targeting another genome sequence UL111a has been described previously 18, 24 .
DNase I digestion
Sequencing
The UK-NEQAS-2014 sample with the higher CMV loads was used for sequencing (specimen 2194). Briefly, following PCR using primers Basel-CMV-UL54_80133_F
and Basel-CMV-UL54_80500_R ( Table 1 ) and verifying PCR products on a 1%
agarose gel, the amplicons were purified using Illustra ExoProStar 1-Step (GE Healthcare, England). The sequencing reaction was performed using the BigDye Terminator v3.1 cycle sequencing kit (Thermo Fisher Scientific, MA, USA), purification Sephadex G-50 Superfine (GE Healthcare, England) and sequencing by capillary electrophoresis on a 3500 Genetic Analyzer (Thermo Fisher Scientific, MA, USA). The sequences were analysed using the CodonCode Aligner (MA, USA) and then submitted to basic local alignment search tool (BLAST) analysis (https://blast.ncbi.nlm.nih.gov/Blast.cgi).
Statistical analysis
A sensitivity analysis was done by limiting dilution using the indicated plasmids at 10 6 ; 10 4
, and 10 2 copies per reaction, followed by two sets of 5-fold replicates of 2-fold dilutions starting from 100 copies/reaction down to 0.39 copies/reaction as described previously 25 . The results of the Roche-CAP/CTM-CMV and the corresponding Basel-CMV-UL54 assays were compared by linear regression and Bland-Altman analysis as described previously 25, 26 . Statistical analysis was performed using ANOVA for multiple comparisons ( Figure 3 and 5) on GraphPad Prism version 7.0c (GraphPad Software, USA).
Results (1005 words)
Primers Basel-CMV-UL54_80133_F and Basel-CMV-UL54_80500_R ( Table 1) were designed to amplify and sequence the presumed UL54 target region in the CMV-AD169 reference strain and in the UK-NEQAS-2014 (distribution no. 3521) sample.
The corresponding 368bp-long amplicons were sequenced and analyzed using BLAST alignment. The UK-NEQAS-2014 sequence was compared with all 329 CMV sequences available in the NCBI GenBank database and phylogenetic analysis was performed using BLAST tree view (Fig. 1) . The alignment identified a total of 43 nucleotide deviations in the presumed UL54 target region (Fig. 1B; suppl. Table 1 ).
The alignment also revealed that the UK-NEQAS-2014 distribution no. 3521 sample had been uploaded in the meantime under the acc. no. KJ361971 (Fig. 1) .
Since no relevant variations were found in the sequence targeted by the forward primer,
Basel-CMV-UL54_80134_F was combined with different reverse primers, which were either specific for CMV-AD169 or the UK-NEQAS-2014 sequence, using the option of degenerate bases to accommodate the sequence variations (Basel-CMV-UL54-361_80494_R) or were additionally moved closer to the forward primer (Basel-CMV- Table 1) . Thereby, four different amplicons were generated of 361bp, 254bp, 151bp, and 95bp, respectively ( Fig. 2A) . For detection, the probe targeted a sequence region close to the forward primer, which had no relevant base variations and which could be used to assay the generation of all four amplicons (Basel-CMV-UL54_80203_80174_P, Table 1 ). To evaluate the impact of the sequence differences, reverse primers harboring degenerate bases were compared with specific primers for the CMV-AD169 and for UK-NEQAS-2014 sequences using 10'000 copies/reaction of the respective plasmids pCMV-AD169-UL54 and pCMV-UKNEQAS2014-UL54 ( CMV-UL54 assays differed in Ct values for the same plasmid copy number (Fig. 3A) .
Thus, the Basel-CMV-UL54-95bp consistently required less amplification cycles for than any of the other Basel-CMV-UL54 having longer amplicons. Review of potential primer and probe incompatibilities including primer dimers was unremarkable. . Both, the Basel-CMV-UL54-95bp (p=0.05) and
Basel-CMV-UL111a-77bp (p<0.05) showed higher viral loads compared to the intended results of this QA probe (Fig. 3C) , whereas the Roche-CAP/CTM-CMV failed to quantify the CMV genome load. Together, the data demonstrated that sequence variability and amplicon size contributed significantly to the variability of CMV DNA loads.
To investigate the impact of the new assays on CMV loads in transplant patients, we retrospectively examined 107 cryopreserved plasma samples submitted for routine CMV load testing using the Roche assay: 50 were below the LOD and found to be positive in 8 cases with 100 copies/mL using the Basel-CMV-UL54-95bp assay. In another 8 samples below LLOQ, but above LOD in the Roche assay, the Basel quantified 5 above 150 copies/mL. Finally, all of the 49 samples above LLOQ in the Roche assay had detectable CMV loads using the Basel-CMV-UL54-95bp, which were significantly higher as compared to the Roche-CAP/CTM-CMV results (Fig. 4A) .
Linear regression and Bland-Altman analyses revealed that this difference amounted to 0.6 log10 copies/mL on average across a range of CMV loads (Fig. 4BC) . To investigate the contribution of unprotected CMV genome fragments, Basel-CMV-UL54-95bp QNAT was performed without or with DNase-I treatment prior to nucleic (Fig. 4D) .
Since freezing and thawing of the plasma samples might affect these results, the Roche-CAP/CTM-CMV and the new Basel-UL54-CMV-95bp; -254bp, and -361bp
were prospectively compared in 69 plasma samples submitted for CMV load testing. Finally, DNase-I treatment of the prospectively collected plasma samples before nucleic acid extraction similarly revealed loss in CMV DNA detection in 42 of 68 samples (61.8%), and a significant decline in CMV loads in the remaining 26 samples (38.2%) for Basel-UL54-CMV-95bp (Fig. 5C) . For Basel-UL54-CMV-254bp and361bp, similar results were obtained. The results indicated that large parts of plasma CMV genomes were not protected suggesting that naked CMV DNA fragments significantly contributed to patient plasma CMV loads.
Discussion (952 words)
The sensitive and specific quantification of CMV replication in peripheral blood is a cornerstone of current clinical management and key to clinical studies 9, 10 . Although the 1 st -WHO-CMV-IS as potentially commutable calibrator has improved result comparability across different laboratories 16, 27 , a general agreement and definition of clinically relevant cut-offs is subject of current investigations 17 . The current study demonstrates that standardization of CMV QNAT is challenged by sequence variability, amplicon length, and non-encapsidated CMV genome fragments, which alone or in combination represent significant obstacles to commutability of blood CMV loads.
As shown here, these challenges arise on several, partly conceptual levels and cannot be solved by solely relying on commercial assay development. In fact, the failure of a .
Our results are in line with this observation in retrospectively and prospectively studied plasma samples reducing CMV loads both qualitatively (by 82% and 76%, respectively), as well as quantitatively.
Thus, the presence of unprotected CMV genomic fragments may potentially limit the value of retrospective studies on frozen samples, especially when using large amplicons that intrinsically underestimate patient viral loads. In how far this affects the strategy of dual-target assays advocated by some centers 31 is presently little studied 24 , but given the goal of defining relevant cut-offs in blood or BAL 32, 33 , dual detection leading to at least 2-fold differences may have an impact on management decisions. Basel-CMV-UL54-360_80493_GAT_R
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